MedTrace Logo

Stimulant Drug Treatment of Attention-Deficit Hyperactivity Disorder (AD/HD), Inattentive Type

NCT00824317 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2009-01-16

No results posted yet for this study

Summary

The purpose of this study is to compare the response to methylphenidate treatment of children with two different subtypes of ADHD.

Conditions

  • ADHD

Interventions

DRUG

methylphenidate

(15 mg daily), medium (25 mg daily) and high (40 mg daily)

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Mary Solanto · Icahn School of Medicine at Mount Sinai

Study Design

Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
7 Years
Max Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-10-31
Primary Completion
2005-02-28
Completion
2005-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00824317 on ClinicalTrials.gov